Document is current
Any future updates will be listed below
-
Authors
Patrick, Matthew T. https://orcid.org/0000-0002-6174-9002
Li, Qinmengge
Wasikowski, Rachael https://orcid.org/0000-0003-3544-3023
Mehta, Nehal
Gudjonsson, Johann E. https://orcid.org/0000-0002-0080-0812
Elder, James T.
Zhou, Xiang https://orcid.org/0000-0002-4331-7599
Tsoi, Lam C. https://orcid.org/0000-0003-1627-5722
-
Funding
Funding for this research was provided by:
National Psoriasis Foundation
Foundation for the National Institutes of Health (K01AR072129, 1P30AR075043)
- License Information
-
More Information
Article History
Received: 8 February 2022
Accepted: 20 October 2022
First Online: 2 November 2022
Competing interests
: J.E.G. has served as a consultant to AbbVie, Eli Lilly, Almirall, Celgene, BMS, Janssen, Prometheus, TimberPharma, Galderma, Novatis, MiRagen, AnaptysBio and has received research support from AbbVie, SunPharma, Eli Lilly, Kyowa Kirin, Almirall, Celgene, BMS, Janssen, Prometheus, and TimberPharma. L.C.T. has received research support from Janssen and Galderma. The remaining authors declare no competing interests.
